CBS 2019
CBSMD教育中心
中 文

Other Relevant Articles

Abstract

Recommended Article

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia Genotype-Guided Strategy for Oral P2Y12 Inhibitors Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents Classification of Deaths in Cardiovascular Outcomes Trials Known Unknowns and Unknown Unknowns Association Between Living in Food Deserts and Cardiovascular Risk High-Risk Coronary Atherosclerosis Is It the Plaque Burden, the Calcium, the Lipid, or Something Else? A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial Management of two major complications in the cardiac catheterisation laboratory: the no-reflow phenomenon and coronary perforations

Guideline2013 Oct;34(38):2949-3003.

JOURNAL:Eur Heart J. Article Link

2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology

Task Force Members, Montalescot G, Sechtem U et al. Keywords: Angina pectoris; Coronary revascularization; Guidelines; Myocardial ischaemia; Risk factors; Stable coronary artery disease; anti-ischaemic drugs

FULL TEXT PDF